Dr. Burns at AAIC ’21

Alzheimer’s Association International conference (AAIC) was held on July 29th – Cassava Sciences presented 9 month cognition data for the first 50 patients enrolled in their open label study. Their slide deck was presented word for word by Dr. Lindsay Burns, SVP and Lead Scientist.

The company used the term encouraging and made no claims of efficacy while describing their results. However, that did not stop many from weighing in. Here are some social media criticisms posted by well known influencers –

Source: twitter

An excerpt from the Adam Feuerstein’s article above:

It’s not hard to see past Adam Feuerstein’s implied misogyny and lack of basic research on a publicly available study design. For the record, Dr. Burns, an author of multiple scientific papers, has the following background

Source: cassavasciences.com/management

Facing criticism for his remarks, Dr. Rob Howard, one of the quoted scientists on the stat+ article, doubled down and posted on his twitter feed.

Source: twitter

Dr. Howard ignored the questions surrounding his role in legitimizing the article while only responding to comments from fans and the harassment from reddit trolls. As for comments from users who asked him to take a look at the data and research – crickets.

Their criticism doesn’t change facts. Dr. Burns emphasized this was an open label study and only large phase 3 studies can prove efficacy. How is doing this overblown, uninterpretable or naive? Is being invited to present inappropriate? Before delivering the presentation, cassava had also announced two phase 3 studies.

It’s hard not to question the motives of these personalities and their backers when they engage in rhetoric. Note that their comments were picked up by various media articles to enable the “sell the news” effect that caused the stock to crater ~50%.

Some questions for these social media influencers,

  • Are companies that complete open label studies not allowed to present results to academia and investors?
  • Is your platform intended to foster progress with constructive criticism or plainly serve as a signal to short sellers and day traders?
  • Are you willing to be gracious and admit missteps when wrong?

There exists a world of folks with honorable reputations, who make questionable comments and never leave their echo chambers. They are mostly right but will never admit it when wrong. This blog hopes to critique these positions.

Author’s thesis on 9 month cognition release

The author of this piece acknowledges that Simufilam is not a proven drug. Preclinical studies on mice models and post mortem human brains have illustrated the mechanism of action. Phase 2 trials have shown encouraging results. The ongoing open label study is using a placebo baseline from a meta-analysis of over 20,000 patients with mild to moderate AD. Since a clinical hallmark of Alzheimer’s disease is decline in cognitive function, the improvements shown over 9 months, despite the placebo effect, is unheard of. The small sample size is the biggest concern and any investment should factor that in.

Biomarker results backing cognition were impressive. Here again it must be noted that biomarkers for Alzheimer’s disease is an active subject of research and the correlation between biomarkers and disease progression hasn’t been completely established. Cassava in their studies so far have found decreases in CSF p-tau 181 best correlates with cognition improvement.



Introduction & Cassava Sciences

This blog was setup to promote small cap bios in the Alzheimers and CNS spaces. Many small biotechs are forced to battle misinformation from social media scientists, wall street short sellers and pump & dump traders. This leads to attacks on the credibility of founders and scientists and causes extreme volatility in share prices.

In such scenarios, some small retail investors who have done their due diligence and who may have critical information to share, often struggle to disseminate information that counters the narrative. For instance these investors may tweet at a widely followed account of a social media scientist or write a comment on the authors blog and receive no responses. Sometimes the errors propagated may be so egregious and even acknowledged by the social media figure but then no follow up actions or corrections are made.

What this blog will specifically do for investors?

  • Provide a platform for vetted retail investors to publish scientific views that counter the prevailing social media sentiment on small cap bios
  • Research the science and provide general insights/opinions including critque of the critics
  • Provide a Q&A with experts in the field

What this blog will not do?

  • Be a platform for unscientific views or promote any sort of hate or misogyny
  • Receive any sort of in kind donation from investors or companies and people associated

The author(s) on this blog may hold short/long positions on the stocks.

The first company we will be covering is Cassava Sciences (Ticker: SAVA), a small cap bio, with its lead drug candidate Simufilam and plasma biomarker candidate SavaDx. A recent FDA petition filed by law firm Labaton Sucharow called into question the science behind the company and asked to halt its phase 3 trials. We will be examining the truth to the allegations using crowdsourced knowledge and responses from Cassava sciences (here and more recently here).

We hope you are open to our views!